Alpha Emitter Market Segment Fueling Growth Of The Overall Market

Market Overview:
Alpha emitter therapies are used in the treatment of various types of cancers like prostate, breast and ovarian cancers. Alpha emitters like actinium-225 and bismuth-213 are directly attached to monoclonal antibodies that bind to cancer cells. They deliver a high dose of radioactivity selectively to the tumor cells while causing minimal damage to normal tissues in the vicinity.

Market key trends:
One of the major trends in the alpha emitter market is the use of Actinium-225 based radiotherapies for the treatment of cancer. Actinium-225 possesses beneficial properties such as a short half-life of 10 days and alpha particle emitting decay which allows it to selectively target cancer cells. Companies such as Actinium Pharmaceuticals and Bayer are developing Actinium-225 based targeted alpha therapies for indications like acute myeloid leukemia, and neuroendocrine tumors. In 2023, Actinium Pharmaceuticals announced positive results from the Phase 1 trial of Actimab-A for relapsed/refractory AML which can potentially progress the drug into further clinical trials.

The global Alpha Emitter Market Share is estimated to be valued at US$ 1,331.0 Mn in 2023 and is expected to exhibit a CAGR of 10.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Segment Analysis
The global alpha emitter market can be segmented based on product, application, end-user, and region. Based on product, the alpha emitter market is segmented into actinium-227, radium-223, and others. The radium-223 segment dominated the market in 2022 as radium-223 has received FDA approval for treatment of castration-resistant prostate cancer. It also provides palliative benefit for bone metastases without severe side effects.

Key Takeaways
The global alpha emitter market is expected to witness high growth, exhibiting CAGR of 10.% over the forecast period, due to increasing prevalence of cancer globally.

Regional analysis
North America is expected to dominate the alpha emitter market during the forecast period. This is primarily attributed to factors such as rising prevalence of cancer, well-established healthcare facilities, and presence of key market players in the region. According to the American Cancer Society, in 2023, around 1.9 million new cancer cases are expected to be diagnosed in the U.S.

Key players
Key players operating in the alpha emitter market are Actinium Pharmaceutical Inc., Alpha Tau Medical Ltd, Bayer AG, Bracco, Cardinal Health, Eckert & Ziegle, Fusion Pharmaceuticals, IBA Worldwide, NorthStar Medical Radioisotopes (NMR), Orano Group, Viewpoint Molecular Targeting, RadioMedix, Telix Pharmaceuticals Limited., TerraPower, LLC, NIOWAVE Inc. and IONETIX Corporation. Actinium Pharmaceutical Inc. and Alpha Tau Medical Ltd are dominating the global alpha emitter market owing to their diverse product offerings.

Read More:

Leave a Comment

Si prega di attivare i Javascript! / Please turn on Javascript!

Javaskripta ko calu karem! / Bitte schalten Sie Javascript!

S'il vous plaît activer Javascript! / Por favor, active Javascript!

Qing dakai JavaScript! / Qing dakai JavaScript!

Пожалуйста включите JavaScript! / Silakan aktifkan Javascript!Better Stop Adblock